Equities analysts predict that Acasti Pharma Inc (NASDAQ:ACST) will announce ($0.11) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Acasti Pharma’s earnings. Acasti Pharma reported earnings of ($0.18) per share in the same quarter last year, which indicates a positive year over year growth rate of 38.9%. The firm is expected to report its next earnings results on Tuesday, August 13th.
According to Zacks, analysts expect that Acasti Pharma will report full-year earnings of ($0.24) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.13). For the next year, analysts anticipate that the business will report earnings of ($0.11) per share, with EPS estimates ranging from ($0.17) to ($0.04). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Acasti Pharma.
ACST has been the subject of a number of analyst reports. Aegis initiated coverage on shares of Acasti Pharma in a report on Tuesday. They set a “buy” rating for the company. ValuEngine raised shares of WPP from a “sell” rating to a “hold” rating in a report on Wednesday, June 19th. Zacks Investment Research lowered shares of Home Bancshares from a “hold” rating to a “sell” rating in a report on Friday, June 7th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of ACASTI PHARM-TS in a report on Wednesday, June 26th.
ACST traded up $0.01 during trading on Friday, reaching $1.41. 5,600 shares of the company’s stock were exchanged, compared to its average volume of 1,693,287. The firm has a fifty day moving average of $1.04. Acasti Pharma has a fifty-two week low of $0.43 and a fifty-two week high of $1.80. The firm has a market cap of $110.64 million, a price-to-earnings ratio of -1.99 and a beta of 1.15.
About Acasti Pharma
Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.
Further Reading: Short Selling Stocks, A Beginner’s Guide
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.